Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT03529227 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Gazyva Infusion Reaction Investigation

GAIRI
Start date: March 31, 2018
Phase:
Study type: Observational

The study evaluate safety and effectiveness of chlorambucil and obinutuzumab in routine clinical practice in patients with chronic lymphatic leukemia and with certain comorbidities (any cardiac pathology, diabetes mellitus (DM), kidney pathology or cytopenia), whom obinutuzumab & chlorambucil have been applied according to indications before enrollment in the study.

NCT ID: NCT03528941 Not yet recruiting - Clinical trials for Chronic Lymphoid Leukemia

The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib

LLC1618
Start date: June 30, 2018
Phase:
Study type: Observational

This observational retrospective study will enroll at least 158 patients affected by Chronic Lymphoid Leukemia (CLL) with previous HBV exposure (HBsAg negative, anti-HBc positive with or without anti-HBs) treated, with Ibrutinib single agent according to the IWCLL criteria 2008. Patients will be divided into two cohorts, one encompassing patients who received lamivudine and the second one including patients who received no prophylaxis. Each patient will be observed for one year from the first administration of Ibrutinib.

NCT ID: NCT03524235 Not yet recruiting - Lymphoma Clinical Trials

Haploidentical Stem Cell Transplant With Prophylactic With Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Start date: May 2018
Phase: Phase 1
Study type: Interventional

This study seeks to examine the investigational use of the conditioning regimen (bendamustine, fludarabine, and retiuximab) prior to haplo peripheral blood allogeneic stem cell transplantation with PTCy. The study will also test the investigational use of CD56-enriched Donor Lymphocyte Infusion to see if this treatment is safe and whether or not it will help patients achieve better outcomes post-transplant, including reduced risk of Graft Versus Host Disease (GVHD) and preventing disease relapse.

NCT ID: NCT03519984 Not yet recruiting - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as recombinant ephb4-HSA fusion protein, cytarabine, and vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving the drugs in different combinations may kill more cancer cells.

NCT ID: NCT03518112 Recruiting - Leukemia Clinical Trials

Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: April 18, 2018
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if blinatumomab given in combination with low-intensity chemotherapy can help to control Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL). The safety and effectiveness of this combination will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of other types of ALL. The chemotherapy used in this study is FDA approved and commercially available for the treatment of ALL. It is considered investigational to use blinatumomab in combination with chemotherapy to treat Ph- ALL. The study doctor can explain how the study drugs are designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03516617 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: May 20, 2018
Phase: Phase 2
Study type: Interventional

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.

NCT ID: NCT03515785 Not yet recruiting - Clinical trials for BCR-ABL Positive Acute Lymphoblastic Leukemia

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Start date: June 15, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®) in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical practice in Europe.

NCT ID: NCT03515200 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: April 20, 2018
Phase: Phase 1
Study type: Interventional

Leukemia cells grow and divide fast and out of control. In normal cells, certain proteins called CDK4 and CDK6 control cell growth. The study drug called palbociclib works by blocking the CDK4 and CDK6 proteins. Palbociclib has been shown to kill leukemia cells in the laboratory and in animal studies. Palbociclib will be added to other chemotherapy drugs, such as dexamethasone, that are known to be effective in treating childhood ALL. This study will be done in two parts: Part 1: Dose Escalation and Part 2: Dose Expansion. The goal of Part 1 of the study is to find the highest tolerable combination of palbociclib and chemotherapy that the investigators can give to patients with leukemia. Once those doses are determined, the investigators will enroll patients on Part 2: Dose Expansion. This phase will enroll additional patients that receive the highest tolerated dose of palbociclib as determined in part 1, in order to better understand the side effects and how effective this treatment approach is. With this research study, the investigators hope to meet the following goals: - To find the highest tolerable dose of palbociclib in combination with chemotherapy that can be given without causing severe side effects; - To learn what kind of side effects palbociclib in combination with chemotherapy may have; and - To learn more about the biology effects of palbociclib on the cells in the participant's body. Up to 40 children, adolescents and young adults will participate in both parts of this study at St. Jude only.

NCT ID: NCT03514017 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Start date: June 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated, high-risk CLL patients. Immune function will be evaluated through various laboratory correlative tests.

NCT ID: NCT03513562 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well venetoclax and ibrutinib work in treating participants with chronic lymphocytic leukemia and have developed genetic mutations after previously being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.